

Special Issue

Contemporary and Future Approaches to Inherited Cardiomyopathies

Message from the Guest Editors

Inherited cardiomyopathies are predominantly caused by variants in genes encoding sarcomeric, cytoskeletal, desmosome, nuclear envelope, enzymes or other proteins (such as transthyretin). While next-generation sequencing has vastly improved our ability to detect these variants, translating genetic insights into meaningful clinical outcomes remains challenging due to incomplete penetrance and environmental factors. This issue of *Cardiogenetics* focuses on the evolving understanding of the genetic, immunologic, and therapeutic dimensions of inherited cardiomyopathies.

This issue emphasizes the need for an integrated perspective that considers the genetic substrate, the phenotypic spectrum, and immune mechanisms when designing therapeutic strategies. By aligning precision diagnostics with immune-aware, gene-based therapies, the field moves closer to delivering transformative, individualized treatments for inherited cardiomyopathies.

Guest Editors

Dr. Michele Ciabatti

Cardiovascular Department, San Donato Hospital, 52100 Arezzo, Italy

Dr. Alessia Argiro

Tuscan Regional Amyloidosis Centre, Careggi University Hospital, 50134 Florence, Italy

Deadline for manuscript submissions

20 December 2026



Cardiogenetics

an Open Access Journal
by MDPI

Impact Factor 0.9
CiteScore 1.4



mdpi.com/si/250293

Cardiogenetics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cardiogenetics@mdpi.com

[mdpi.com/journal/
cardiogenetics](https://mdpi.com/journal/cardiogenetics)





Cardiogenetics

an Open Access Journal
by MDPI

Impact Factor 0.9
CiteScore 1.4



[mdpi.com/journal/
cardiogenetics](https://mdpi.com/journal/cardiogenetics)



About the Journal

Message from the Editor-in-Chief

Cardiogenetics is an essential resource for general physicians, cardiologists, and geneticists. Exome sequencing, noncoding DNA, bioinformatics, micro-RNA, long-noncoding DNA and epigenetics have entered our daily vocabulary, highlighting the importance of forming a “cardiogenetics team” working side by side, bringing the lab to the patients’ bed, and vice versa. A strong Editorial Board of active clinicians and scientists will support this new experience. *Cardiogenetics* publishes high-quality original research papers, review articles, short reports, news and views, with the aim of connecting the scientific (bench) to the clinical (bedside) world. Since 2011, the journal has been increasingly successful. Please help us to overcome this challenge.

Editor-in-Chief

Dr. Giuseppe Limongelli

Department of Translational Medical Sciences, Inherited and Rare Heart Disease, Vanvitelli Cardiology, University of Campania Luigi Vanvitelli, 80131 Naples, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within ESCI (Web of Science), Scopus, Embase, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 23.1 days after submission; acceptance to publication is undertaken in 6.2 days (median values for papers published in this journal in the second half of 2025).